Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
MT-027 in Glioblastoma, IDH-Wildtype: NCT07386002 Clinical Landscape Report 2026
18 September 2026
NCT07386002 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acetylcysteine in Glioblastoma Multiforme: NCT07387666 Clinical Landscape Report 2026
18 September 2026
NCT07387666 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pucotenlimab in Renal Cell Carcinoma: NCT07386158 Clinical Landscape Report 2026
18 September 2026
NCT07386158 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Glioblastoma, IDH-Wildtype: NCT07385846 Clinical Landscape Report 2026
18 September 2026
NCT07385846 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Renal Cell Carcinoma: NCT07389629 Clinical Landscape Report 2026
18 September 2026
NCT07389629 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT07391215 Clinical Landscape Report 2026
18 September 2026
NCT07391215 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Diffuse midline glioma, point mutation K27M in histone H3: NCT07389278 Clinical Landscape Report 2026
18 September 2026
NCT07389278 clinical landscape for Diffuse midline glioma, point mutation K27M in histone H3: endpoints, sponsor, phase, geography, readouts, asset context a…
9 min read
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT07397832 Clinical Landscape Report 2026
18 September 2026
NCT07397832 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Triple Negative Breast Cancer: NCT07394387 Clinical Landscape Report 2026
18 September 2026
NCT07394387 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tovecimig in Recurrent Glioblastoma: NCT07392957 Clinical Landscape Report 2026
18 September 2026
NCT07392957 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in ER-positive/HER2-negative Breast Cancer: NCT07408089 Clinical Landscape Report 2026
18 September 2026
NCT07408089 clinical landscape for ER-positive/HER2-negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Zimberelimab in Renal Cell Carcinoma: NCT07397611 Clinical Landscape Report 2026
18 September 2026
NCT07397611 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.